Watching a cancer patient endure the excruciating pain of conventional treatment is always disheartening. It can instill a sense of fear of not only of cancer but also the treatment. However, in the face of such adversity, there are individuals who see opportunities to make the situation better and more bearable. One such individual is Clay Siegall, the founder and current president, chief executive officer and chairman of Seattle Genetics. Witnessing a relative go through the ordeal of conventional cancer treatment while at the university stirred a strong passion in him to find alternative and more effective cancer treatment. It is this passion that he has pursued single-handedly.
In 1998, he cofounded Seattle Genetics and has directed the company’s activities towards finding effective therapy for cancer. One such successful therapy is the FDA-approved ADCetris, which has brought in significant revenues for the company in addition to the patents sold. Clay Siegall has been steadfast in his management of the company, guiding the company through financial difficulties. His strong belief in teamwork has seen guide the company to important milestones such as initial public offer (IPO), which helped the company end a decade-long operation without making profits.
Academic Background and Scholarly Endeavors
Clay Siegall is one of the leading scholars on cancer research with up to 15 patents already registered to his name. His long commitment to understanding cancer and finding an effective cure has also seen publish up to 70 articles. His interest in cancer research and treatment development began while he was at the University of Maryland studying for his Bachelor of Science degree in Zoology. He later furthered his interest in the subject by studying for his PhD in Genetics at George Washington University.
Award-winning Entrepreneurship and Management
Clay Siegall has been awarded the prestigious Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012 in recognition for his excellent management at Seattle Genetics, which he cofounded. He was also honored by his alma mater, University of Maryland, for outstanding work. His tenure at the helm of the company has seen it partner with other key industry players in cancer research and development of revolutionary therapies while also spearheading an initiative that helped in raising over $1.2 billion in capital for research.